N. Boeckx MD, PhD

P06 Targeted single cell sequencing unravels the heterogeneity of human T-cell acute lymphoblastic leukemia samples

PP30 Retrospective study of de novo and secondary myeloid sarcoma

P2.02 Belgian consensus on the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria

P3.02 Ponatinib as bridge to haematopoietic stem cell transplantation in a patient with a myeloid/lymphoid neoplasm with eosinophilia and abnormality of FGFR1: a case report

P4.03 Comparison of GeneXpert BCR-ABL Monitor and GeneXpert BCR-ABL Ultra assay for the quantification of BCR-ABL1 in CML patients under TKI treatment

Use of multiparameter flow cytometry in multiple myeloma and other plasma cell neoplasms

Summary

Flow cytometric immunophenotyping is recommended for diagnosis, classification and monitoring of disease in monoclonal gammopathies. Furthermore, it is a useful diagnostic tool for clinical practice and has various applications, such as its ability to distinguish between normal, reactive and malignant plasma cells, to evaluate the risk of progression from monoclonal gammopathy of undetermined significance to plasma cell myeloma, to provide prognostic information, to evaluate the presence of minimal residual disease and to identify new therapeutic targets. The incorporation of novel therapies in the management of patients diagnosed with plasma cell neoplasms has increased depth and frequency of response, as well as prolonged progression free and overall survival. Along with these improvements in therapeutic strategies, definition of responses to treatment has evolved over time. It was therefore necessary to develop reproducible and sensitive assays for detection and monitoring of minimal residual disease and to define its prognostic value in predicting progression free and overall survival, to allow for consolidation and maintenance therapeutic strategies and to evaluate the efficacy of novel therapies.

(BELG J HEMATOL 2015;6(2):46–53)

P1.01 Flow cytometric screening in patients at risk for paroxysmal nocturnal hemoglobinuria and evaluation of clone sizes: a retrospective study